Pharmaceutical proteomics.
Genomics and proteomics are today well established in drug discovery and, in combination with combinatorial chemistry and high-throughput screening, are helping to bring forward an unprecedented number of potential lead compounds. To avoid the generation of bottlenecks downstream in drug development, increasing pressure is arising to integrate these technologies into the development environment. Proteomics has demonstrated proof-of-concept in toxicology as shown by a number of successful applications in mechanistic toxicology and lead selection. The "technology wave" is now starting to impact the clinical phase of drug development. Expected benefits are optimized clinical trials based on the availability of biologically relevant markers of drug efficacy and safety.
Steiner
S
S
Large Scale Proteomics Corporation, Rockville, Maryland 20850-3338, USA. sandra.steiner@lsbc.com
Anderson
N L
NL
D000818:Animals; D016572:Cyclosporine / Q000633:toxicity; D015195:Drug Design; D064420:Drug-Related Side Effects and Adverse Reactions; D004852:Epoxy Compounds / Q000494:pharmacology / Q000633:toxicity; D015870:Gene Expression / Q000187:drug effects; D020869:Gene Expression Profiling; D006801:Humans; D008099:Liver / Q000187:drug effects; D020543:Proteome / Q000032:analysis*
D004852:Epoxy Compounds; D020543:Proteome; D016572:Cyclosporine; C054207:etomoxir